Evidence map›Paper›PMID 24616545›Full record

GuidelineJournal of the National Comprehensive Cancer Network : JNCCN2014

Merkel cell carcinoma, version 1.2014.

Christopher K Bichakjian, Thomas Olencki, Murad Alam, James S Andersen, Daniel Berg, Glen M Bowen, Richard T Cheney, Gregory A Daniels, L Frank Glass, Roy C Grekin and 21 more

Abstract readPractice Guideline
In one paragraph

Guideline in Journal of the National Comprehensive Cancer Network : JNCCN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. A Review of Cutaneous Diseases Observed in Solid Organ Transplant Recipients.The Journal of clinical and aesthetic dermatology · 2022
    Review
  6. Article
  7. Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Christopher K Bichakjian
Thomas Olencki
Murad Alam
James S Andersen
Daniel Berg
Glen M Bowen
Richard T Cheney
Gregory A Daniels
L Frank Glass
Roy C Grekin
Kenneth Grossman
Alan L Ho
Karl D Lewis
Daniel D Lydiatt
William H Morrison
Kishwer S Nehal
Kelly C Nelson
Paul Nghiem
Clifford S Perlis
Ashok R Shaha
Wade L Thorstad
Malika Tuli
Marshall M Urist
Timothy S Wang
Andrew E Werchniak
Sandra L Wong
John A Zic
Karin G Hoffmann
Nicole R McMillian
Maria Ho
National comprehensive cancer network

Funding

Viral oncoprotein targeted immune therapy for Merkel cell carcinomaR01CA176841 · NCI · UNIVERSITY OF WASHINGTON · PI NGHIEM, PAUL · 2013 to 2016
$2.6M
NCI NIH HHS R01 CA176841
6 · The paper itself

Abstract

Merkel cell carcinoma is a rare, aggressive cutaneous tumor that combines the local recurrence rates of infiltrative nonmelanoma skin cancer with the regional and distant metastatic rates of thick melanoma. The NCCN Guidelines for Merkel Cell Carcinoma provide recommendations on the diagnosis and management of this aggressive disease based on clinical evidence and expert consensus. This version includes revisions regarding the use of PET/CT imaging and the addition of a new section on the principles of pathology to provide guidance on the analysis, interpretation, and reporting of pathology results.

Indexed as

Carcinoma, Merkel CellHumansSkin Neoplasms

Identifiers

PMID24616545
PMCPMC9441108

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.